|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock-based compensation expense | |||||
| Depreciation expense | |||||
| Non-cash lease expense | |||||
| Loss on disposal of equipment | |||||
| Change in fair value of warrant liability | |||||
| Class C Common Stock Warrant | |||||
| Total change in fair value of warrant liability | |||||
| Issuance of common stock for services | |||||
| Changes in operating assets and liabilities: | |||||
| Prepaid expenses and other current assets | |||||
| Deferred offering costs | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Operating lease liability | |||||
| Accrued interest on Promissory Notes Payable & Convertible Note | |||||
| Net cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchase of property and equipment | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities: | |||||
| Repayment of the Convertible Note | |||||
| Proceeds from the PIPE Investment, net | |||||
| Repurchase for the Forward Share Purchase Agreement exercise | |||||
| Repayments of Promissory Notes Payable, including interest | |||||
| Proceeds From Public Offering Net | |||||
| July 2022 Public Offering | |||||
| February 2023 Public Offering | |||||
| Redemption of Series A Preferred Stock | |||||
| Net cash provided by financing activities | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||
| Fair Value of Common Stock Warrants | |||||
| Class G Common Stock Warrants | |||||
| Class F Common Stock Warrants | |||||
| Fair Value of Common Stock Warrants in connection with Warrant Inducement | |||||
| Common Class E | |||||
| Class D Common Stock Warrants | |||||
| Class I Common Stock Warrants | |||||
| Equity issuance costs in connection with the Warrant Inducement included in accounts payable and accrued expenses | |||||
| Equity issuance costs in connection with the Class D Warrant Inducement included in accounts payable | |||||
| Class D Common Stock Warrants | |||||
| Total equity issuance costs in connection with the Class D Warrant Inducement included in accounts payable | |||||
| Fair Value of Common Stock Warrants in connection with Public Offering | |||||
| Deemed dividend for exercise price reductions of warrants | |||||
| Operating lease right-of-use asset exchanged for lease liability | |||||
| Alternative cashless exercises of Common Stock Warrants | |||||
| Class C Common Stock Warrant | |||||
| Class F Common Stock Warrants | |||||
| Total alternative cashless exercises of Common Stock Warrants | |||||
| Deferred underwriting commissions assumed in the Business Combination | |||||
| Equity Issuance for fees in connection with the Business Combination | |||||
| Issuance of Common Warrants in connection with the PIPE Investment | |||||
| Issuance of Placement Agent Warrants in connection with the PIPE Investment | |||||
| Conversion of Accrued Expenses to Equity in connection with the Business Combination | |||||
| Issuance of Class B Common Stock Warrants in connection with the July 2022 Public Offering | |||||
| Issuance of Class B Placement Agent Common Stock Warrants in connection with the July 2022 Public Offering | |||||
| Deferred offering costs included in accounts payable and accrued expenses | |||||
Loading...